DUROLANE 60MG/3ML SYRINGE

Packaging

Indications and usage

For the symptomatic treatment of mild to moderate osteoarthritis of the knee or hip joint.

Contraindications

Carefully: in patients with signs of impaired venous or lymphatic drainage in the lower extremities.

Dosage and administration

Recommended dose: 3 ml (one syringe) per knee or hip joint.

The course of treatment requires a single injection of the drug.
Treatment of osteoarthritis of the hip joint

Intra-articular injection into the hip joint should be carried out under x-ray control (preferably using a radiopaque substance) or under ultrasound control in order to ensure the correct position of the needle in the joint cavity.

With the introduction of the needle is recommended the use of local anesthetics.

An introduction to the hip joint should be done by a physician experienced in this type of injection.

The recommended needle length 130 mm № 18-21.

Adverse reactions

In the treatment of osteoarthritis of the knee: transient pain, swelling, restriction of movements in the area of ​​the knee.

The severity of side effects: mild to moderate degrees, with an average duration of one week.

In the treatment of osteoarthritis of the hip joint: exacerbation of pre-existing pain, restriction of movement in the hip joint for up to 12 days.

Only a small number of patients need to use painkillers or NSAIDs.

Special notes

Durolane should be used with caution in patients with signs of impaired venous or lymphatic drainage in the lower extremities.

The study Dyuralana was not conducted in pregnant women, as well as in children.

For bilateral treatment, separate syringes should be used for each knee or hip joint.

Do not use local painkillers, if you know that the patient is allergic or hypersensitive to local anesthetics.

It is not necessary to carry out an injection into the hip joint under X-ray control using radiopaque substances, if it is known that the patient has an allergy or hypersensitivity to radiopaque substances.

General precautions for intra-articular injections should be observed.

The introduction of the drug Durolane ® should be carried out only by a doctor in a medical facility in a room equipped for intra-articular administration of drugs.

With the introduction of the drug should strictly follow the rules of asepsis.

The injection site before administration must be swabbed with alcohol or another appropriate antiseptic.

Access for drug administration should be selected so as to avoid damage to nearby vital structures. Durolane ® should be injected only into the joint cavity.

Before the introduction of the drug must be removed effusion from the joint, if any. Use the same needle to remove effusion and administer Durolane ®.

It is recommended to use needles of size from 18G to 22G of sufficient length.

The product is intended for single use and should not be re-sterilized. It must be used immediately after removing the syringe from the packaging. If the blister pack or syringe is damaged, then the drug can not be used.

As with other invasive treatments, overloading (playing tennis, running or walking) should be avoided for the first two days after the injection.

You can expect a transient reaction to the introduction of the drug: pain and / or swelling, restriction of movements of mild or moderate severity during the first week after injection. If these symptoms continue for more than one week, then you should consult a doctor.

Keep away from sunlight at a temperature of 20 ° C to 30 ° C, do not freeze.